Diffusion Pharmaceuticals (DFFN) Given a $1.00 Price Target by HC Wainwright Analysts

HC Wainwright set a $1.00 price objective on Diffusion Pharmaceuticals (NASDAQ:DFFN) in a report published on Monday morning. The firm currently has a buy rating on the stock.

NASDAQ:DFFN opened at $0.57 on Monday. Diffusion Pharmaceuticals has a one year low of $0.50 and a one year high of $3.93.

TRADEMARK VIOLATION WARNING: “Diffusion Pharmaceuticals (DFFN) Given a $1.00 Price Target by HC Wainwright Analysts” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/17/diffusion-pharmaceuticals-dffn-given-a-1-00-price-target-by-hc-wainwright-analysts.html.

About Diffusion Pharmaceuticals

Diffusion Pharmaceuticals Inc, formerly RestorGenex Corporation, is a clinical-stage biotechnology company. The Company is focused on developing standard-of-care treatments, including radiation therapy and chemotherapy. The Company’s lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC) is used in various cancer types, in which tumor oxygen deprivation (hypoxia) is known to diminish the effectiveness of treatments.

Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply